Forus, the AI platform for medicine previously known as Tandem, said it has raised $150 million in Series C financing at a $3 billion valuation. Bain Capital Ventures led the round, with participation from Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures and SV Angel.
The company says its platform connects doctors, pharmacies, payers and biopharma, handling the administrative work between a provider prescribing a medication and a patient starting treatment. According to the announcement, providers in all 50 states use Forus to treat patients in 85% of U.S. residential zip codes. In total, the company has raised more than $300 million.
How The Platform Is Positioned
Forus is focused on the operational bottlenecks that sit between a prescription and first dose. CEO Sahir Jaggi said one-third of patients prescribed medications for high-cost or complex conditions never receive their first dose, leaving providers to fall back on older and more accessible treatments instead of newer therapies that may offer better outcomes and fewer side effects.
Jaggi said a single prescription can require up to 15 steps across insurance approvals, financial assistance, specialty pharmacy routing and fulfillment. Forus’ answer is to give each prescription an AI agent that reasons through a patient’s clinical, insurance and financial circumstances and then takes the actions required to move the patient from prescription through treatment.
This is a narrower and more commercially concrete use of AI than drug discovery narratives that depend on future pipeline wins. The claim here is not that AI creates medicines; it is that AI can reduce the friction that prevents already approved or prescribed medicines from reaching patients. If that operational layer becomes embedded in clinical workflows, the value accrues through network effects across providers, pharmacies, payers and manufacturers.
Where The New Capital Goes
Jaggi said the Series C proceeds will be used in three areas: deepening the platform with more AI agents and clinical models, expanding to all medical specialties and sites of care, and growing the company’s technical and go-to-market teams.
That spending plan suggests Forus sees its next phase less as a single-product buildout than as category expansion. A company already operating nationwide and claiming broad zip-code reach is using fresh capital to widen specialty coverage and add more intelligence layers, which indicates management believes the adoption bottleneck is no longer just proving the concept.
Bain Capital Ventures framed the company in network terms. General partner Kevin Zhang said in a statement that “Forus is becoming how new medicine reaches people in America” and that “the next era of medicine will run on the AI-powered network Forus is building.” Investor language is often promotional, but the valuation itself signals that backers are assigning strategic value to the company’s place in the medication access workflow, not only to software efficiency.
The larger bet is that controlling the prescription-to-treatment handoff could matter to biopharma economics as much as marginal gains in commercialization tools. Jaggi said making the development, launch and delivery of each medicine faster, less expensive and more predictable should allow biopharma companies to invest in more medicines and more indications. That is an ambitious claim, but it captures why investors may view Forus as infrastructure rather than just another healthcare automation vendor.
